🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07598019
Starting soon Observational

Effects of Remimazolam on Neurocognitive Function in Patients Undergoing Cardiovascular Surgery

NCT07598019 · tracked via the Priya Life Science China tracker
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Phase
Observational
Started
2026-06-15
Last updated
2026-05-20

Condition(s) studied

Neurocognitive DisorderCardiac Surgery

Study summary

The goal of this observational study is to explore the effect of remimazolam-based total intravenous anesthesia on postoperative neurocognitive function in patients who undergo cardiovascular surgery.

The main question this study tries to answer is: Does remimazolam influence the incidence of postoperative delirium in cardiovascular surgery? Participants already apply remimazolam-based total intravenous anesthesia as part of their regular medical treatment for general anesthesia to perform cardiac surgery will answer questionnaires about cognitive function after surgery.

Eligibility

Sex
ALL
Min age
60 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Male or female adult patients aged 60 years or older 2. Receiving elective cardiovascular surgery with cardiopulmonary bypass 3. Written Informed consent provided Exclusion Criteria: 1. Deep hypothermia circulatory arrest 2. Breastfeeding or pregnancy 3. Mental or legal disability 4. Terminal illness with a life expectancy of less than 3 months 5. Unable to receive neuro-cognitive evaluation due to language, vision, or hearing impairments

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College Beijing Beijing Municipality

More Chinese Academy of Medical Sciences, Fuwai Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07598019 on ClinicalTrials.gov ↗ ← All trials in China